Evaluation of zinc sulfate effect in prevention of chemotherapy-induced mucositis in Patients with cancer referred to Emam Ali Hospital in 2008-2009

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201101023133N3

Enrollment

Registered

2011-02-01

Start date

2008-08-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy-induced mucositis. Other and unspecified lesions of oral mucosa

Interventions

Intervention 1: Control group/Placebo: three placebo capsules daily (Alhavi Co.), initiation of chemotherapy until the end of chemotherapy phase. Intervention 2: Intervention group/Drug: three 220-mg

Prevention

Control group/Placebo: three placebo capsules daily (Alhavi Co.), initiation of chemotherapy until the end of chemotherapy phase.

Intervention group/Drug: three 220-mg zinc sulfate capsules daily (Alhavi Co.), initiation of chemotherapy until the end of chemotherapy phase

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: chemotherapy treatment with a regimen that had the same mucositis probability, Karnovsky performance status case equal or more than 60, life expectancy equal to or more than 6 months, White Blood Cell count equal to or more than 1500 and platelet count equal to or more than 100000/µL Exclusion criteria: radiotherapy in the head and neck region, including nasopharynx, oropharynx, and larynx previously or simultaneously, previous head and neck surgery due to malignancy, use of dentures, pregnancy, infection

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Mucositis. Timepoint: Two weeks after initiation of chemotherapy and every two weeks until. Method of measurement: The patients are examined under a headlight, using dental explorers and mirrors. Data were recorded. Oral mucositis patients were labelled from 0 to 4 ,using World Health.	—

Secondary

Measure	Time frame
Pain. Timepoint: Two weeks after initiation of chemotherapy and every two weeks untilthe end of chemotherapy phase. Method of measurement: The patients are examined under a headlight, using dental explorers and mirrors. Data were recorded. Oral mucositis patients were labelled from 0 to 4 ,using World Health.;Xerostomia. Timepoint: Two weeks after initiation of chemotherapy and every two weeks untilthe end of chemotherapy phase. Method of measurement: The patients are examined under a headlight, using dental explorers and mirrors. Data were recorded.;Quality of life. Timepoint: Two weeks after initiation of chemotherapy and every two weeks untilthe end of chemotherapy phase. Method of measurement: Quality of life a questionnaire(EORTC LQ-OES18) is filled out each meeting individually by the dental student.	—

Measure

Time frame

Pain. Timepoint: Two weeks after initiation of chemotherapy and every two weeks untilthe end of chemotherapy phase. Method of measurement: The patients are examined under a headlight, using dental explorers and mirrors. Data were recorded. Oral mucositis patients were labelled from 0 to 4 ,using World Health.;Xerostomia. Timepoint: Two weeks after initiation of chemotherapy and every two weeks untilthe end of chemotherapy phase. Method of measurement: The patients are examined under a headlight, using dental explorers and mirrors. Data were recorded.;Quality of life. Timepoint: Two weeks after initiation of chemotherapy and every two weeks untilthe end of chemotherapy phase. Method of measurement: Quality of life a questionnaire(EORTC LQ-OES18) is filled out each meeting individually by the dental student.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMarzie Deghatipour

Zahedan University of Medical Sciences

marzie_deghatipour@yahoo.com+98 54 1241 4004

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026